Hear Why J&J Medtech Is Ready to Move Forward with Ottava; A VC Discusses the Impact of GLP-1 drugs
In this week’s episode we’ll speak with Rocco De Bernardis, Global President of OTTAVA. Johnson & Johnson Medtech. This week, J&J Medtech announced it was filing an IDE to begin clinical trials on its surgical robotics system, Ottava, in 2024. But what does this mean? What does Ottava look like? Why does J&J Medtech think it has what it takes to win over surgeons? And what does the future look like for the company’s surgical robotics platform?
Co-hosts Tom Salemi and Chris Newmarker also chat with Karthik Bolisetty, senior associate at VC firm Gilde Healthcare, about the impact GLP-1 drugs could have on medical device start-ups. How does Gilde see the weight loss drugs impacting its portfolio and future investments?
Finally, Gregg Tobin, CEO of Aptyx, our episode sponsor, talks about how the company’s new name better reflects its capabilities. Go to Aptyx.com for more information.
Thanks for listening to the DeviceTalks Weekly podcast.
Subscribe to the DeviceTalks Podcast Network on any major podcast application.
Co-hosts Tom Salemi and Chris Newmarker also chat with Karthik Bolisetty, senior associate at VC firm Gilde Healthcare, about the impact GLP-1 drugs could have on medical device start-ups. How does Gilde see the weight loss drugs impacting its portfolio and future investments?
Finally, Gregg Tobin, CEO of Aptyx, our episode sponsor, talks about how the company’s new name better reflects its capabilities. Go to Aptyx.com for more information.
Thanks for listening to the DeviceTalks Weekly podcast.
Subscribe to the DeviceTalks Podcast Network on any major podcast application.
Activity